GCM
ABOS icon

Gladius Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Gladius Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,939
Closed -$26.5K – 278
2024
Q2 		$26.5K Buy
+10,939
New +$34.8K ﹤0.01% 294

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Gladius Capital Management's ABOS Position: Q3 2024 in Review

Gladius Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q3 2024, closing a stake of 10,939 shares — an estimated $26.5K sold.

Gladius Capital Management first reported a position in ABOS in Q2 2024 and held it in 1 quarter. The position peaked at $26.5K in Q2 2024. 73 funds tracked by Wall St. Rank hold ABOS as of Q3 2024.

  • Gladius Capital Management reported no remaining Acumen Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Gladius Capital Management sold 10,939 Acumen Pharmaceuticals shares in Q3 2024, an estimated $26.5K.
  • Gladius Capital Management first reported a position in Acumen Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Gladius Capital Management's Acumen Pharmaceuticals position peaked at $26.5K in Q2 2024.
  • 73 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2024.

Based on Gladius Capital Management's 13F filing for Q3 2024, filed 6 Nov 2024.